Drug-drug Interaction Clinical Trial
Official title:
A Phase 1, Open-Label, Three-Period, Single-center Study to Assess the Pharmacokinetic Interactions Between ZSP1273 and Oseltamivir in Healthy Subjects
Verified date | October 2021 |
Source | Guangdong Raynovent Biotech Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.
Status | Completed |
Enrollment | 36 |
Est. completion date | March 17, 2021 |
Est. primary completion date | March 17, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Males and female subjects between 18-45 years (Both inclusive); - Body weight is no less than 50kg in males and no less than 45kg in females.Body mass index (BMI) 18~26 kg/m2 (Both inclusive); BMI is determined by the following equation: BMI = weight/height2 (kg/m2); - Subjects (including partners) are willing to voluntarily use effective contraception from screening to 3 months after the last study drug administration. Exclusion Criteria: - Known history of allergic constitution (multiple drugs especially with ZSP1273 or oseltamivir and its preparation of the main ingredient allergy, food allergy); - Subjects who donated blood or bleeding profusely(> 450 mL)in the 3 months preceding study screening; - History or presence of any disease or condition known to increase the risk of bleeding, eg.hemorrhoids, acute gastritis or gastric and duodenal ulcer, etc; - Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal within 14 days prior to screening; - Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents that may change the activity of drug metabolic enzymes ,is intended to be taken in combination 28 days prior to screening or during the study period; - Participated in another clinical research study or received any investigational products within 3 months prior to dosing; - Presence of clinically significant abnormalities in ECG , QTcB>450ms in males,or QTcB>470ms in females; - Any of the following diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular diseases) that are clinically significant in clinical laboratory examination or other clinical findings within 6 months prior to screening; - Breast-feeding women or those with positive pregnancy test results; - Subjects who should not be included in the study in the opinion of the Investigator. |
Country | Name | City | State |
---|---|---|---|
China | Guangdong Provincial Hospital of Chinese Medicine | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangdong Raynovent Biotech Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma pharmacokinetics | Tmax | pre-dose and up to 72hours post-dose | |
Primary | Plasma pharmacokinetics | t1/2 | pre-dose and up to 72hours post-dose | |
Primary | Plasma pharmacokinetics | Cmax | pre-dose and up to 72hours post-dose | |
Primary | Plasma pharmacokinetics | AUC0-8 | pre-dose and up to 72hours post-dose | |
Primary | Plasma pharmacokinetics | CL/F | pre-dose and up to 72hours post-dose | |
Primary | Number of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) | TEAEs will be summarized displaying the number of TEAEs along with the number and percentage of participants with at least one TEAE according to: Number of AEs, Severity and relation to study drug. | up to 37days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05692570 -
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04328766 -
Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03990129 -
Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03985969 -
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
|
Phase 1 | |
Completed |
NCT03302845 -
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02887443 -
A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate
|
Phase 1 | |
Completed |
NCT01361217 -
The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
|
N/A | |
Completed |
NCT06066060 -
A DDI Study of JMKX000623 and Metformin Hydrochloride
|
Phase 1 | |
Completed |
NCT03723395 -
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
|
Phase 1 | |
Recruiting |
NCT05789173 -
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
|
Early Phase 1 | |
Completed |
NCT04598542 -
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05044962 -
Kuwa Free! - Live Free!
|
N/A | |
Completed |
NCT04487145 -
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
|
Phase 4 | |
Active, not recruiting |
NCT04669678 -
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
|
Phase 4 | |
Completed |
NCT01991327 -
Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
|
Phase 1 | |
Completed |
NCT04218513 -
Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection
|
Phase 1 | |
Completed |
NCT05492318 -
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
|
Phase 1 | |
Completed |
NCT01309854 -
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05339672 -
Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
|
||
Completed |
NCT05306379 -
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
|
Phase 1 |